Kim Klein

Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group.

D. Johnston, S. Raimondi, T. Alonzo, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treating CD33-Positive de novo Acute Myeloid Leukemia in Pediatric Patients: Focus on the Clinical Value of Gemtuzumab Ozogamicin

C. Zwaan, G. Kaspers, K. Klein, 2023, OncoTargets and therapy.

Causes of early death and treatment‐related death in newly diagnosed pediatric acute myeloid leukemia: Recent experiences of the Dutch Childhood Oncology Group

C. Zwaan, W. Tissing, N. Dors, 2019, Pediatric blood & cancer.

Glucocorticoid‐Induced Proliferation in Untreated Pediatric Acute Myeloid Leukemic Blasts

C. Zwaan, E. Haarman, U. Creutzig, 2016, Pediatric blood & cancer.

Repurposing CD19-directed immunotherapies for pediatric t(8;21) acute myeloid leukemia

Annelisa M Cornel, F. Barneh, G. Kaspers, 2024, bioRxiv.

Clinical challenges in de novo pediatric acute myeloid leukemia

G. Kaspers, V. de Haas, K. Klein, 2018, Expert review of anticancer therapy.

Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study Group

G. Leverger, R. Gerbing, S. Ha, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.